Figure 2.

Combination KLRG1 and PD-1 therapy synergizes to decrease B16-E-cadherin tumor burden

(A) Flow cytometry profile of B16-F10 melanoma or B16-E-cadherin melanoma stained with an anti-PD-L1 mAb. (B) C57BL/6 mice were subcutaneously injected with 2 × 10⁵ B16-E-cadherin cells. Tumor-bearing mice were treated with isotype control, anti-KLRG1 mAb, anti-PD-1 mAb or anti-KLRG1 + anti-PD-1 mAbs on day 7, 10, 13, and 16 post-tumor cell implantation. Tumor volume was measured via caliper every three days (n = 8–13). (C) Flow cytometry characterization of tumor infiltrating NK and CD8⁺ T cells from isotype control treated mice day 22 post-tumor implantation. Spleen was used as control. Upper panel: representative staining profiles of KLRG1 and PD-1 expression on tumor infiltrating NK and CD8⁺ T cells. Lower panel: Pie chart analysis of KLRG1 and PD-1 expression (mean ± SD) (n = 8–13). (Data are representative of (A, C) or pooled from two experiments (B, C), error bars indicate S.E.M.) *p < .05, **p < .01, ***p < .001, and ****p < .0001.